Targets › UNC13A
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Sep 2027.
Plays a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway. Involved in neurotransmitter release by acting in synaptic vesicle priming prior to vesicle fusion and participates in the activity-dependent refilling of readily releasable vesicle pool (RRP). (UniProt, Q9UPW8)
Open in Phaseline: the race on UNC13A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Trace Neuroscience | TRCN-1023 UNC13A function restoration therapy | UNC13A | Phase 1 | Amyotrophic Lateral Sclerosis | Sep 2027 |
Amyotrophic Lateral Sclerosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.